Plain-English translation of NCT07679399 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a newer treatment approach—combining durvalumab with chemotherapy drugs followed by lenvatinib—can better prevent biliary tract cancer from coming back after surgery, compared to taking alone. Biliary tract cancer is a rare cancer affecting the tubes that carry bile. This medication approach uses both immunotherapy (which helps your immune system fight cancer) and targeted therapy to try to keep cancer from returning.
Currently, is the standard pill that patients take after surgery to reduce the risk of cancer returning. Doctors want to know if this newer combination treatment might work better and keep patients cancer-free longer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new combination treatment or the standard pill. The combination group will receive chemotherapy and durvalumab infusions for several months, followed by lenvatinib pills. The standard group will take pills. You will have regular clinic visits, blood tests, and imaging scans to monitor how well the treatment is working and watch for side effects. The study will track whether your cancer returns and how you tolerate the treatment over time.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China